

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
26 October 2023 (26.10.2023)



(10) International Publication Number
WO 2023/203549 A1

(51) International Patent Classification:

A61P 17/06 (2006.01) C07K 16/24 (2006.01)

(21) International Application Number:

PCT/IB2023/054122

(22) International Filing Date:

21 April 2023 (21.04.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/333,920 22 April 2022 (22.04.2022) US

(71) Applicant: **MOONLAKE IMMUNOTHERAPEUTICS AG** [CH/CH]; Dorfstrasse 29, 6300 Zug (CH).

(72) Inventor: **REICH, Kristian**; c/o MoonLake Immunotherapeutics AG, Dorfstrasse 29, 6300 Zug (CH).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))
- in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

(54) Title: METHODS OF ACHIEVING SAFE AND SUSTAINED CONTROL OF IL-17-DEPENDENT CONDITIONS IN SUBJECTS RESPONSIVE TO TREATMENT WITH AN ANTI-IL 17A/F NANOBODY

(57) Abstract: Disclosed herein are methods of treating psoriasis and other IL-17-dependent conditions with an anti-interleukin 17A/F nanobody for approximately 24 weeks, followed by withdrawal of treatment in responding patients with the anti-interleukin 17A/F nanobody for a period of at least 4-20 weeks. Disease modification may be achieved by no later than week 24 with the anti-interleukin 17A/F nanobody such that responders may demonstrate sustained normalization of peripheral and/or cutaneous biomarkers such as IL-17A, IL-17F, and/or IL-22. Treatment methods as contemplated herein which have been paused may be re-started based on the subject's condition. Treatment beyond 24 weeks also achieves unexpectedly high efficacy in responders who have not quite reached full skin clearance in the initial treatment period.



WO 2023/203549 A1